Skip to content
sellModerate cluster of 5

Carole Huntsman sold $181k of MDGL

Chief Commercial Officer at MADRIGAL PHARMACEUTICALS, INC.. 419 shares at an average of $431.94, traded Mar 6, 2026, filed Mar 6, 2026.

Warning score
42
Value
$181k
419 shares
Holdings after
12,692
-3% from before
From 52-week low
+62%
low $267.56, close $432.83
From 52-week high
-28%
high $602.83, as of Mar 6, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $181k at market
    +12
  • Share of holdings sold
    Sold 3.2% of holdings
    0
  • Cluster
    5 insiders selling within 14 days
    +15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +26.4%, 3m +12.5%, 6m +25.0%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

MDGLOct 9, 2026 · close 471.75
Since filing Mar 6, 2026: +9.0%SPY +16.7% · excess -7.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001628280-26-015758, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 4, 2026AGrant or award
Common Stock
+3,989$0.00$013,111Mar 6, 2026
Mar 6, 2026SOpen-market sale
Common Stock
-419$431.94$181k12,692Mar 6, 2026
Mar 4, 2026AGrant or award
Stock Option (Right to Buy)derivative
+4,986$0.00$04,986Mar 6, 2026

Related signals

Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
MDGLsell10b5-1
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$6.2M
11,583 shares
-6%
21Weak
MDGLsell 210b5-1
MADRIGAL PHARMACEUTICALS, INC.
David Soergel
Chief Medical Officer
$517k
1,042 shares
-9%
33Weak
MDGLsell 210b5-1
MADRIGAL PHARMACEUTICALS, INC.
Richard S Levy
director
$2.9M
5,682 shares
-21%
40Moderate
MDGLsell 2
MADRIGAL PHARMACEUTICALS, INC.
David Soergel
Chief Medical Officer
$435k
844 shares
-7%
45Moderate
MDGLsell 510b5-1
MADRIGAL PHARMACEUTICALS, INC.
Mardi Dier
EVP and CFO
$854k
1,982 shares
-14%
41Moderate
MDGLsell 5
MADRIGAL PHARMACEUTICALS, INC.
Shannon T Kelley
General Counsel
$155k
360 shares
-3%
42Moderate
MDGLsell 5
MADRIGAL PHARMACEUTICALS, INC.
Rebecca Taub
director
$212k
491 shares
-0%
61Notable
MDGLsell 5
MADRIGAL PHARMACEUTICALS, INC.
William John Sibold
President and CEO
$718k
1,663 shares
-1%
60Notable
MDGLsell 5
MADRIGAL PHARMACEUTICALS, INC.
Mardi Dier
EVP and CFO
$505k
1,183 shares
-11%
27Weak
MDGLsell 410b5-1
MADRIGAL PHARMACEUTICALS, INC.
Carole Huntsman
Chief Commercial Officer
$449k
910 shares
-9%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Carole Huntsman sold $181k of MDGL | InsiderTell